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Tobacco harm reduction: the devil is in the deployment
The concept of harm reduction in tobacco control is exciting interest among policy makers and
industry. Gerard Hastings, Marisa de Andrade, and Crawford Moodie argue that it presents
public health with some challenges
Gerard Hastings professor, Marisa de Andrade research fellow, Crawford Moodie senior research
fellow
Institute for Social Marketing, University of Stirling, Stirling FK9 4LA, UK
The idea of tobacco harm reduction—that smokers who cannot
wean themselves off nicotine should be encouraged to adopt
less harmful ways of consuming it—has much to recommend
it. It avoids the trap of making the excellent (complete cessation)
the enemy of the good (reduced harm) and provides a way
forward where otherwise there is only a cruel impasse. It also
provides a clear focus on disease and premature death—rather
than tobacco addiction or corporate power—and this enemy,
like so many medical problems before it, will be defeated with
rigorous evidence, effective medicines, and skilled treatment.
In the United Kingdom the National Institute for Health and
Clinical Excellence has just produced draft guidelines on harm
reduction approaches to smoking and the Medicines and
Healthcare Products Regulatory Agency is considering licensing
electronic cigarettes.1 These moves are in response to the
emergence of a range of nicotine containing products that seem
suitable for temporary or indefinite use as partial or complete
substitutes for tobacco. These include nicotine replacement
therapy (patches, sprays, gums, lozenges, inhalators), licensed
by the MHRA as pharmaceutical treatments for smoking, and
unlicensed products such as topical gels and a burgeoning array
of electronic cigarettes (e-cigarettes). This proliferation of
nicotine containing products raises the classic public health
question: what happens when a good idea at an experimental
level is taken to scale? The answer is complicated by business
interests: both the tobacco and pharmaceutical industries are
keen to exploit harm reduction.
What does harm reduction offer tobacco
control?
As noted by NICE,1 harm reduction may help smokers with no
intention or ability to quit to gradually wean themselves off
cigarettes. For people who have tried everything to quit but
simply cannot manage without nicotine, the case for harm
reduction seems self evident: immediate lives will be saved.
However, a broader perspective suggests potential problems.
Firstly, the new nicotine containing products are not intuitively
appealing; smokers will need to be persuaded of their benefits.
For public health there is a key benefit: it is easier to use them
than to quit. But for most smokers quitting is the best option
and should be presented as achievable and attractive. So rolling
out harm reduction puts public health in the contradictory
position of having to stress both the difficulties and attractions
of quitting.
A related danger is that children will pick up on this apparent
confusion. While previous generations were told simply that
tobacco is bad; new ones would learn that nicotine is acceptable,
just be careful how you access it. Moreover, promotion of harm
reduction might reduce the perceived “cost” of uptake. Finally,
the fact that e-cigarettes deliberately mimic conventional ones
(even down to emitting fake smoke)may result in the inadvertent
modelling of smoking (box 1).
More broadly, the media, which (at least in the UK) has become
a reliable supporter of comprehensive control measures, might
also struggle with this more complex position. Thus the benefits
of harm reduction are not as obvious as they first seem. The two
corporate players will further muddy the water.
What is in it for the tobacco industry?
It is nearly half a century since the tobacco industry recognised
that it is “in the business of selling nicotine, an addictive drug.”2
Nevertheless, it has been notoriously shy about this reality, so
much so that 30 years after the original admission it was
prepared to perjure itself to the US Congress rather than even
admit that nicotine is addictive—let alone that it would ever
exploit the resulting human frailty.3 Harm reduction, however,
introduces the possibility of public health formally recognising
that selling recreational nicotine is an acceptable—even
good—idea, provided you clean up the delivery mechanism.
The tobacco industry’s marketing skills could help smooth the
difficult transition from tobacco to e-cigarettes, but again there
are concerns. Harm reduction is more profitable than abstinence
but not than continued smoking. And even in an advanced
tobacco control market like the UK, the tobacco industry stills
gets over 99% of its profits from smoked tobacco.4 Given this
Correspondence to: G Hastings gerard.hastings@stir.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e8412 doi: 10.1136/bmj.e8412 (Published 17 December 2012) Page 1 of 5
Analysis
ANALYSIS
Box 1: Using harm reduction to promote smoking
Brand stretching—Major smoked tobacco brands, including Marlboro (fig 1⇓), Lucky Strike, and Peter Stuyvesant, have been attached
to harm reduced snus products providing respectability by association just as Camel boots and Marlboro Classic clothing did a generation
ago.
Evocative advertising—Non-tobacco harm reduction products are being promoted with evocative advertising (fig 2⇓). Addition of tobacco
branding to packaging could make the distinction between their use and smoking harder to draw
Undermining smoke-free ordinances—Smokeless products (whether tobacco based or not) are being promoted as “work friendly” or
“when smoking isn’t an option” and so are presenting an alternative to quitting in the face of smoke-free ordinances
Modelling—Electronic cigarettes are designed to mimic real ones, and this may reinforce the idea of smoking
asymmetry, the industry is inevitably using harm reduction to
boost the much more profitable conventional products (box 1).
Hence the tobacco industry’s involvement in harm reduction is
mired in double standards. When British American Tobacco
(BAT), for instance, calls for a broader approach “that accepts
that many adults are going to continue to use tobacco and
nicotine products,”5 the words are overshadowed by the fact
that the majority of the company’s marketing budget is focused
on encouraging continued smoking. And when the company
says that it has “a responsibility to pursue ways in which we
might reduce the health risks of our products” the reflex response
from public health has to be: “Stop marketing them so
assiduously across the globe.”
Even when the tobacco industry genuinely pursues the
non-tobacco nicotine market, there are concerns. The
profitability of the cigarette lies principally in the fact that most
smokers stick with the habit (and the product) for decades. The
tobacco companies will want to repeat this success with
e-cigarettes: they will use their marketing muscle to ensure that
consumers continue to use their products for as long as possible.
Tobacco companies are also using harm reduction in their
stakeholder marketing6—the efforts they put into building links
with powerful subgroups in society. BAT’s recent Sustainability
Report, for example, emphasises how it is “preparing for the
future” by “engaging with regulators, scientists and the public
health community to develop the scientific and regulatory
frameworks needed to deliver reduced-risk products.”7 The fact
that two years ago the company’s head of public health and
scientific affairs was invited by NICE to present to its Citizen’s
Council on harm reduction, shows it is succeeding.8 Such
collaboration could easily undermine the World Health
Organization’s Framework Convention on Tobacco Control,
which outlaws working with the tobacco industry.
What is in it for the pharmaceutical
industry?
In 2009 the UK nicotine replacement therapymarket was worth
£125m, and in 2011 the UK government spent £66.4m on
subsidising these products.9 10 Significant though these sums
are, they represent only 1% of the value of the tobacco market,
mainly because usage is measured in weeks, rather than the
decades for tobacco. Just like the tobacco companies, then, the
drug industry wants to extend the duration of use, which explains
why it has been so active in the legitimisation of harm reduction
(box 2).
Like tobacco companies, the pharmaceutical industry will use
its marketing skills to keep people in the nicotine market. This
task will be made easier by the NICE guidelines, which explain
that licensed nicotine containing products, while intended for
short term use, are considered suitable for use in the medium
term—and even as lifelong substitutes for cigarettes.1
Harm reduction also offers the drug companies useful
stakeholder marketing opportunities: it enables them tomaintain
and enhance relationships with the same scientists and policy
makers that the tobacco industry is courting.
Shared interests
Thus both the tobacco and pharmaceutical industries have a
vested interest in a legitimised market for nicotine and links
between the two sectors can only increase. BAT’s recent launch
of a subsidiary called Nicoventures to focus on the “development
and commercialisation of innovative regulatory approved
nicotine products”14 is a harbinger of things to come.
Harm reduction also raises more fundamental questions about
the role of public health. Specifically, we need to ask whether
its job is to save or to empower. If it is to save, then getting
people to stop smoking using whatever means possible becomes
the priority—and leaving them dependent on nicotine is not a
concern compared with the harm avoided. The second
perspective, however, suggests a need to think not just about
tobacco but diet, alcohol use, exercise, and the many other
behaviours that affect health outcomes. Broader, health
promoting perspectives are needed that focus on the areas that
motivate people and “give them the confidence that they can
change.”15 From this standpoint, harm reduction’s
accommodation with ongoing nicotine dependence is much
more problematic.
More widely still, a key concern with tobacco is that it ties
people to an exploitative multinational industry; harm reduction
merely changes the identity of this industry. Comparisons with
coffee have been made in response to this, equating caffeine
with nicotine. For the most part this parallel does not stand up
to closer analysis (box 3), but the trades in coffee and tobacco
do have one important commonality. Both markets provide
numerous examples of producers being exploited and damaged
by multinationals.16 Public health should be just as concerned
about this form of harm as it is about that caused by chemical
toxins.
The debate about harm reduction needs to encompass this
broader level of analysis—to recognise that the framing we
noted in the first paragraph that the enemy is disease and
premature death not tobacco addiction or corporate power is,
in the real world, simply naive. It ignores the politics of health
and the multiple flaws in the system.
Conclusion
Harm reduction matters. There have to be alternatives for those
who cannot quit. Furthermore, the commercial opportunities
for both the tobacco and pharmaceutical industries mean it is
here to stay. The question is how public health should respond.
The issues are fraught, but five conclusions are clear:
• Collaboration with the tobacco industry is likely to backfire.
The industry’s overwhelming dependence on smoked
tobacco sales means that, for the foreseeable future, harm
reduction will be the servant of this much bigger unhealthy
cause
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Box 2: The pharmaceutical industry’s role in driving forward harm reduction
The process started by promoting the idea to the MHRA that nicotine replacement therapy (NRT) could be a stepping stone to quitting11 as
well as a direct cessation aid. Next the concept of harm reduction was fostered when the manufacturer of the Nicorette inhalator formally
requested an extended application for its product. The MHRA agreed the extension, saying:
“Nicorette Inhalator relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated
to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative
to smoking for smokers and those around them.”12
The report went on to conclude: “In addition, the Working Group recommended a ‘harm reduction’ element was appropriate for the indications
of all other currently authorised forms of NRT.”
In February 2010 the MHRA recognised that “the extension of the indication for NRT to include harm reduction raises the question of the
regulation of other unlicensed nicotine containing products on the market such as electronic cigarettes, which have not been assessed for
safety, quality, and efficacy.”13
An entirely new treatment had emerged for the problem of smoking.
Box 3: Coffee and tobacco—key differences
The coffee industry is argued to be another multinational exploiting our dependence on a drug (in this case caffeine) yet this raises few
concerns; by extension a market in nicotine could become as innocent as our morning cuppa. However, there are three crucial differences:
• Caffeine consumption is not linked to any major health problems; while nicotine itself seems to be relatively harmless, its addictive
properties mean that the most nicotine consumption is, and will continue to be for the foreseeable future, extremely unhealthy
• Caffeine consumption is not related to disadvantage; nicotine consumption is deeply regressive
• Caffeine is only a small part of the coffee story as the popularity of decaffeinated coffee attests; de-nicotined cigarettes have proved
a much less attractive consumer proposition
• Collaboration with the pharmaceutical industry is also
problematic because its priority will always be private
profitability rather than public health. This will be
manifested in a focus on prolonging use, which could mean
indefinite use
• In the long term, the aim of both industries is to stimulate
and grow the market in nicotine, and immense marketing
effort will be used to further this strategy
• Harm reduction has the potential to deflect the strategic
direction of tobacco control. Benefits need to be judged
not just in the narrow sense of lives saved among users but
by comparison with other tobacco control options and the
contribution to a comprehensive strategy
• It is important to think beyond the UK. If the government
continues to collaborate with the tobacco industry on harm
reduction, this will confer a dangerous legitimacy that will
be exploited in other countries with much less advanced
tobacco control policies and undermine the Framework
Convention on Tobacco Control.
Harm reduction is a potentially valuable tobacco control tool,
but it needs to be taken forward with great care. Anything
approaching public health backed population level
implementation is likely to do more harm than good.
The MRHA is currently considering the licensing of
e-cigarettes.1 Until this happens, their safety and efficacy
remains unproved and they should not be recommended for
cessation or harm reduction. If a licence is issued, marketing
restrictions should be extremely tight to avoid counterproductive
promotion. The controls implemented in New Zealand, where
e-cigarettes cannot be used therapeutically, provide a good
model (box 4).17 In addition, any tobacco brand sharing must
be treated as a breach of the UK advertising ban. Robust research
programmes should also be put in place to monitor the effect
of harm reduction so that the regulatory regime can be adjusted
as needed (box 5).
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Box 4: Restrictions on promotion of e-cigarettes in New Zealand17
E-cigarettes cannot be promoted:
• As gadgets
• As social props
• As dual purpose products along with cigarettes
• As flavoursome products for enjoyment
• In places where smoking is prohibited
• As an alternative to smoking
• As a cooler and safer way to smoke
Box 5: Key research questions
• How many smokers opt for nicotine long term, either through choice or as a consequence of multiple failed quit attempts?
• What harm reduction approaches are smokers currently using, are these changing, and what effect do they have on different
subpopulations (eg, young people)?
• What is the effectiveness of harm reduction on smoking rates at a population level?
• Are there unintended consequences of harm reduction strategies?
• What are the health benefits of reduced consumption with the help of licensed nicotine-containing products rather than unaided, with
self help materials, or using different behavioural strategies?
• How will the tobacco and drug industries use harm reduction in their business strategies?
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Figures
Fig 1 Marlboro advert for snus
Fig 2 Recent advert for e-cigarettes from New York
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